Anyone looking for some insight into just how hot gene therapies have become should turn their attention today to the behind-the-scenes negotiations that went into Biogen’s $800 million deal to buy Nightstar Therapeutics $NITE.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,